The phase I/II PETRA trial evaluated AZD5305 as monotherapy in patients with advanced metastatic breast, pancreatic, or prostate cancer with germline BRCA1, BRCA2, PALB2, or RAD51C mutations [106]. This evidence concerns the gene BRCA1 and prostate carcinoma.